Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bismuth subnitrate is a highly water-soluble crystalline compound used primarily as an antacid and anti-diarrheic agent. It has been employed in the treatment of duodenal ulcers and gastrointestinal disorders due to its supposed antacid and mildly astringent actions. Bismuth subnitrate exerts protective effects on the gastric mucosa by forming a barrier over ulcer sites and may also disrupt bacterial cell walls, inhibit bacterial enzymes critical for survival, and prevent bacterial adherence to the gastric lining. It is approved by the FDA for use as an active ingredient in over-the-counter antacids. Additionally, it has topical applications for skin disorders, wounds, burns, hemorrhoids, and other anorectal conditions[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bismuth subnitrate.